AG00I7PA

389-08-2 | 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-

AG00I7PA

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	389-08-2
Catalog Number	AG00I7PA(AGN-PC-0RHZ8M)
Chemical Name	1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-
EC Number	206-864-7
IUPAC Name	1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
InChI	InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
InChI Key	MHWLWQUZZRMNGJ-UHFFFAOYSA-N
MDL Number	MFCD00006884
Molecular Formula	C12H12N2O3
Molecular Weight	232.2353
SMILES	CCn1cc(C(=O)O)c(=O)c2c1nc(C)cc2
UN Number	3249
UNII	3B91HWA56M
Synonyms	Acid, Nalidixic, Anhydrous, Nalidixate Sodium, Nalidixate Sodium, Nalidixate Sodium Anhydrous, Nalidixic Acid, Nalidixin, Nevigramon, Sodium Anhydrous, Nalidixate, Sodium Nalidixic Acid, Anhydrous, Sodium Nalidixic Acid, Monohydrate, Sodium, Nalidixate, nalidixic acid, 389-08-2, Nalidixin, Nevigramon, Nalidixate, Uronidix, Innoxalon, Nalidixan, Nalitucsan, Sicmylon, Unaserus, Nalidic acid, NegGram, Nalidixinic acid, Wintomylon, Dixiben, Dixinal, Jicsron, Nalurin, Naxuril, Nogram, Urisal, Cybis, Nalix, 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid, Acide nalidixique, Nalidicron, Betaxina, Kusnarin, Narigix, Nicelate, Specifen, Specifin, Uralgin, Uriclar, Urodixin, Negram, Poleon, Uriben, Uroman, Uroneg, Uropan, Naldixic acid, Acido nalidixico, Acidum nalidixicum, Eucistin, Acide nalidixico, Nalidixane, Wintron, naladixic acid, 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid, NSC-82174, WIN 18,320, Acido nalidissico [DCIT], Acide nalidixico [Italian], Acide nalidixique [French], NCI-C56199, 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid, 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one, Acide nalidixique [INN-French], Acido nalidixico [INN-Spanish], Acidum nalidixicum [INN-Latin], 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-, 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one, UNII-3B91HWA56M, MFCD00006884, NALIDIXATE SODIUM, 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid, CCRIS 2365, HSDB 3241, 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid, 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure, EINECS 206-864-7, Nalidixic acid (NegGram), BRN 0750515, MLS000028504, 3B91HWA56M, Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico, 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German], CHEBI:100147, MHWLWQUZZRMNGJ-UHFFFAOYSA-N, Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian], NSC82174, Win 18320, NCGC00018181-08, SMR000058264, DSSTox_CID_912, 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid, Acido nalidissico, Nalidixic acid, 99.5%, 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, DSSTox_RID_75859, DSSTox_GSID_20912, Nalidixic, 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-, CAS-389-08-2, NegGram (TN), Nalidixic acid USP27, Sodium Nalidixic Acid, Monohydrate, Nalidixic acid [USAN:INN:BAN:JAN], Innoxalomn, Nalidixinsaure, Eucisten, SR-01000003086, wil 18,320, ZERO/002632, WIN-18320, WIN 183203, CHEMBL5, Spectrum_000918, Nalidixic-acid(NegGram), Nalidixic acid [USAN:USP:INN:BAN:JAN], Maybridge1_007101, Opera_ID_1064, Prestwick0_000187, Prestwick1_000187, Prestwick2_000187, Prestwick3_000187, Spectrum2_001360, Spectrum3_000075, Spectrum4_000817, Spectrum5_001540, Nalidixic acid, >=98%, UPCMLD-DP129, N-1200, AC1L1I4P, NCIOpen2_004342, Lopac0_000837, Oprea1_010545, SCHEMBL21736, BSPBio_000113, BSPBio_001889, KBioGR_001333, KBioSS_001398, 5-25-07-00384 (Beilstein Handbook Reference), MLS001148578, MLS002303041, MLS004820190, MLS006011875, BIDD:GT0529, DivK1c_000058, SPECTRUM1500756, SPBio_001579, SPBio_002034, AC1Q310A, BPBio1_000125, DTXSID3020912, UPCMLD-DP129:001, BDBM21691, CTK1C2660, HMS500C20, HMS561K17, KBio1_000058, KBio2_001398, KBio2_003966, KBio2_006534, KBio3_001109, KS-00000XTB, ZINC57421, NINDS_000058, HMS1921G10, HMS2092K04, HMS2232H24, HMS3259O13, HMS3374G11, HMS3656K05, LS-72, Pharmakon1600-01500756, Nalidixic acid (JP17/USP/INN), Nalidixic acid, analytical standard, ALBB-021275, HY-B0398, Tox21_110835, Tox21_201477, Tox21_302754, ANW-42195, BBL012279, CCG-39298, NegGram;Nevigramon;Nalidixin;Uronidix, NSC757432, SBB002146, STK735579, 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid, 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid, AKOS000120074, Tox21_110835_1, CS-2493, DB00779, MCULE-6808033849, NC00494, NSC-757432, RTR-015647, IDI1_000058, NCGC00018181-01, NCGC00018181-02, NCGC00018181-03, NCGC00018181-04, NCGC00018181-05, NCGC00018181-06, NCGC00018181-07, NCGC00018181-09, NCGC00018181-10, NCGC00018181-12, NCGC00018181-13, NCGC00021730-03, NCGC00021730-04, NCGC00021730-05, NCGC00021730-06, NCGC00021730-07, NCGC00256581-01, NCGC00259028-01, AK163550, AN-23434, AS-13289, CPD000058264, H816, NCI60_041807, SAM002554914, SC-18641, SMR004703506, WLN: T66 BN EV JNJ B2 DVQ I1, SBI-0050814.P003, AB0013282, AB2000553, TR-015647, 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-, BB 0242389, FT-0603390, N0490, S2328, SW219624-1, 1-Ethyl-1,8-naphthyridine-3-carboxilic acid, 1-Ethyl-1,8-naphthyridine-3-carboxylic acid, VU0239598-6, C05079, D00183, K-8443, Nalidixic acid, meets USP testing specifications, 389N082, SR-01000003086-4, SR-01000003086-6, BRD-K47886988-323-03-0, I14-18919, Nalidixic acid, Antibiotic for Culture Media Use Only, SR-01000003086-10, F0850-6751, Z256708444, 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid, Nalidixic acid, European Pharmacopoeia (EP) Reference Standard, Nalidixic acid, United States Pharmacopeia (USP) Reference Standard, 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-, 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid, 1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid, InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17, N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide, Acid, Nalidixic, Nacid, Sodium,Nalidixate, Wintomylon (TN), Sodium, Nalidixate, Nalidixic acid sodium, Nalidixic acid sodium salt, Nalidixate sodium anhydrous, D07JGT, Anhydrous, Nalidixate Sodium, Sodium Anhydrous, Nalidixate, Sodium Nalidixic Acid, Anhydrous, C12H12N2O3, CID4421, Nalidixic acid (JP15/USP/INN), WIN-18320 (TN), 1,8-naphthyridine-3-carboxylic Acid, C12-H12-N2-O3, CS-O-02000, Nalidixic acid, 99% - 100G 100g, B1985, D009268, na, NIX,

Complexity	378
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	232.085g/mol
Formal Charge	0
Heavy Atom Count	17
Hydrogen Bond Acceptor Count	5
Hydrogen Bond Donor Count	1
Isotope Atom Count	0
Molecular Weight	232.239g/mol
Monoisotopic Mass	232.085g/mol
Rotatable Bond Count	2
Topological Polar Surface Area	70.5A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	1.4

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H350-H360
Packing Group
Precautionary statements	P280-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number